 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Immtech International, Inc.
 |
Immtech International, Inc. |
 |
 |
 |
PROFILE |
 |
Immtech International's products stunt growth, but that's the idea behind them. The development-stage company focuses on developing dications, compounds that inhibit the growth of such unpleasant guests as bacteria, viruses, and parasites. Its targets include cryptosporidiosis, hepatitis C, drug-resistant tuberculosis, and a form of pneumonia common to people with weak immune systems. Its NextEra Therapeutics joint venture with Franklin Research Group focuses on C-reactive proteins, which may boost the body's ability to fight cancer and AIDS. An alliance with a consortium of universities led by the University of North Carolina at Chapel Hill gives Immtech access to funding and technology.
COMPETITION |
 |
Abbott Laboratories (ABT)
Eli Lilly and Company (LLY)
Hoffmann-La Roche Inc. (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: March
2001 Sales (mil.): 1.40
1-Yr. Sales Growth: 250.0%
Employees: 9
Revenue per employee: $155,555.56
KEY PEOPLE |
 |
T. Stephen Thompson
CEO
Gary C. Parks
CFO
CONTACT INFO |
 |
150 Fairway Dr.
Vernon Hills, IL 60061
US
Phone: 847-573-0033
Fax: 847-573-8288
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |